Markers of Monocyte Activation, Inflammation, and Microbial Translocation Are Associated with Liver Fibrosis in Alcohol Use Disorder

dc.contributor.authorFuster, Daniel
dc.contributor.authorGarcia Calvo, Xavier
dc.contributor.authorFarré, Oriol
dc.contributor.authorZuluaga, Paola
dc.contributor.authorBolao, Ferran
dc.contributor.authorLeis, Alba
dc.contributor.authorHernández Rubio, Anna
dc.contributor.authorRivas, Inmaculada
dc.contributor.authorMuga, Robert
dc.date.accessioned2021-09-13T06:51:04Z
dc.date.available2021-09-13T06:51:04Z
dc.date.issued2021-08-08
dc.date.updated2021-09-10T10:35:05Z
dc.description.abstractBackground: The association between markers of inflammation (interleukin (IL)-6 and IL-10), monocyte activation (sCD163 and sCD14), and microbial translocation (lipopolysaccharide (LPS) and LPS binding protein) and liver fibrosis in patients with alcohol use disorder (AUD) and no overt liver disease is not well established. Methods: We studied patients admitted for treatment of AUD at two hospitals in Barcelona. Advanced liver fibrosis (ALF) was defined as FIB-4 > 3.25. Results: A total of 353 participants (76.3% male) were included and 94 (26.5%) had ALF. In adjusted correlation analyses, sCD163, sCD14, IL-6, IL-10, and LPS binding protein levels directly correlated with FIB-4 values (adjusted correlation coefficients 0.214, 0.452, 0.317, 0.204, and 0.171, respectively). However, LPS levels were inversely associated with FIB-4 (-0.283). All plasma marker levels in the highest quartile, except LPS, were associated with ALF (sCD163, sCD14, IL-6, IL-10, and LPS binding protein: adjusted odds ratio (aOR) 11.49 (95% confidence interval 6.42-20.56), 1.87 (1.11-3.16), 2.99 (1.79-5.01), 1.84 (1.11-3.16), and 2.13 (1.30-3.50), respectively). Conversely, LPS levels in the lowest quartile were associated with ALF (aOR 2.58 (1.48-4.58), p < 0.01). Conclusion: In AUD patients, plasma levels of the markers of inflammation, monocyte activation, and microbial translocation are associated with ALF.
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2077-0383
dc.identifier.pmid34441792
dc.identifier.urihttps://hdl.handle.net/2445/179959
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm10163496
dc.relation.ispartofJournal of Clinical Medicine, 2021, vol. 10, num. 16, p. 3496
dc.relation.urihttps://doi.org/10.3390/jcm10163496
dc.rightscc by (c) Fuster, Daniel et al, 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationAlcoholisme
dc.subject.classificationComorbiditat
dc.subject.otherAlcoholism
dc.subject.otherComorbidity
dc.titleMarkers of Monocyte Activation, Inflammation, and Microbial Translocation Are Associated with Liver Fibrosis in Alcohol Use Disorder
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
jcm-10-03496-v2.pdf
Mida:
802.09 KB
Format:
Adobe Portable Document Format